Immunome Presents Preclinical Data Showing Proprietary TOP1i ADC Payload HC74 Overcomes Multiple Mechanisms of ADC Resistance

Core Insights - Immunome, Inc. is focused on developing innovative targeted cancer therapies, specifically through its proprietary antibody-drug conjugate (ADC) technology [1] - The company recently presented preclinical data indicating that its ADC payload HC74 can overcome various mechanisms of ADC resistance, such as payload efflux and target heterogeneity [1] - HC74 is identified as a novel topoisomerase I inhibitor and is utilized in the ROR1-targeted ADC IM-1021, which is currently undergoing Phase 1 clinical trials [1]